Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VIVO Cannabis Inc. V.PDA


Primary Symbol: VVCIF

VIVO Cannabis Inc is a Canada-based company. It is involved in the production and sale of medical and recreational cannabis and the provision of cannabis-related medical information and services in Canada. The company's operating segment includes Cannabis, Patient Clinics, and Corporate. It generates maximum revenue from the Cannabis segment. The company has a presence across three geographical locations - Canada, Germany, and Australia.


OTCQB:VVCIF - Post by User

Post by 1hot-techwomanon Oct 17, 2019 2:09pm
147 Views
Post# 30240839

Current Target is $1.80 ! Bring on Edibles and 600 % ROI...

Current Target is $1.80 ! Bring on Edibles and 600 % ROI...The first half of 2019 has been focused on increasing VIVOs production capacity. With the recent doubling of capacity at both our Canna Farms and Vanluven facilities, we have been very successful in that regard, CEO Barry Fishman said. Our goal has always been to increase long-term shareholder value by establishing ourselves as a premium provider of cannabis products and services. We are lowering our cost per kilogram through increased production capacity, thereby realizing economies of scale. Zandberg notes that Vivos topline fell short of his expectation of $6.5-million. He explained what happened to produce the result. VIVOs revenue declined compared to Q4 FY18 partly due to initial product stocking for the adult-use market by provincial distributors that benefited the Company, the analyst explains. Management also highlighted that $4M of the total revenue came from cannabis sales in BC. VIVO only sold 215kg of cannabis during the quarter vs. 342kg in the previous quarter, highlighting its slow roll out in the adult-use market post legalization. In a research update to clients today, Zandberg maintained his Buy rating but trimmed his price target on VIVO from $2.00 to $1.80, implying a return of 157 per cent at the time of publication.
<< Previous
Bullboard Posts
Next >>